Trial · NCT01215929
Studying Amphetamine Withdrawal in Humans
NCT01215929, Phase 2, Completed, University of Arkansas; results first posted 2014-08-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Studying Amphetamine Withdrawal in Humans. Trials, record NCT01215929. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01215929
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Studying Amphetamine Withdrawal in Humans
- NCT number
- NCT01215929
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 35 participants, actual
- Lead sponsor
- University of Arkansas
- Conditions
- Methamphetamine Dependence
- Interventions
- Dextroamphetamine, Placebo
- First posted
- 2010-10-07
- Last updated
- 2014-08-04
- Results first posted
- 2014-08-04
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Measure of Methamphetamine Withdrawal | at the end of week 4 | Total score on the Methamphetamine Withdrawal Assessment scale (MAWA) based on DSMIV criteria for amphetamine withdrawal. This questionnaire is comprised of 13 items which describe symptoms associated with the cessation of chronic amphetamine use for which participants indicate severity on a 4-point scale. The minimum score indicating no methamphetamine withdrawal symptoms is 0 and the maximum score is 4 indicating that a patient has the most severe withdrawal symptom related to that question. The subscales are the 13 questions and the total score is the sum of all the scores for the 13 items on the scale. The range minium and better outcome is a lower score. The range is from 0-52. The worse outcome is reflected in a higher score. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Measure of Methamphetamine Withdrawal | at the end of week 4 | units on a scale | LEAST_SQUARES_MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Measure of Methamphetamine Withdrawal | Dextroamphetamine | 3.7283 | Standard Error 3.37 | units on a scale | |
| Measure of Methamphetamine Withdrawal | Placebo | 10.056 | Standard Error 3.45 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dextroamphetamine | 18 | |
| Overall Study | STARTED | Placebo | 17 | |
| Overall Study | COMPLETED | Dextroamphetamine | 12 | |
| Overall Study | COMPLETED | Placebo | 12 | |
| Overall Study | NOT COMPLETED | Dextroamphetamine | 6 | |
| Overall Study | NOT COMPLETED | Placebo | 5 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Insomnia | Psychiatric disorders | Dextroamphetamine | 3 | 18 | |
| other | Insomnia | Psychiatric disorders | Placebo | 2 | 17 | |
| other | Headache | Nervous system disorders | Dextroamphetamine | 2 | 18 | |
| other | Headache | Nervous system disorders | Placebo | 3 | 17 | |
| other | Tachycardia | Cardiac disorders | Dextroamphetamine | 3 | 18 | |
| other | Tachycardia | Cardiac disorders | Placebo | 6 | 17 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dextroamphetamine | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Dextroamphetamine | 8 | 18 |
| Total, other adverse events | Placebo | 9 | 17 |
| Total, serious adverse events | Dextroamphetamine | 0 | 18 |
| Total, serious adverse events | Placebo | 0 | 17 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Dextroamphetamine vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01215929
GET https://conductscience.org/api/trials/v1/NCT01215929/registered